Telix Pharmaceuticals (NASDAQ: TLX) names interim chair after Tiffany Olson resigns
Filing Impact
Filing Sentiment
Form Type
6-K
Rhea-AI Filing Summary
Telix Pharmaceuticals Limited has announced a leadership change at the Board level. Ms. Tiffany Olson has resigned as Non-Executive Director and Board Chair, effective 3 February 2026.
Long-standing independent Non-Executive Director Dr. Mark Nelson has been appointed Interim Chair. The Board states it is in advanced stages of appointing new Non-Executive Directors and is committed to naming a new Independent Chair as soon as feasible. Dr. Nelson emphasized appreciation for Olson’s service and reiterated that Telix has a strong commercial business and pipeline, and that this governance change is not expected to affect delivery of near-term milestones or the company’s long-term growth strategy.
Positive
- None.
Negative
- None.
Insights
Board chair steps down; interim chair appointed, strategy reiterated.
Telix Pharmaceuticals reports the resignation of Board Chair and Non-Executive Director Tiffany Olson, effective 3 February 2026. Long-serving independent director Dr. Mark Nelson moves into the Interim Chair role, providing continuity at the Board level.
The company notes that the Board is in advanced stages of adding new Non-Executive Directors and intends to appoint a new Independent Chair as soon as feasible. This suggests an ongoing refresh of governance rather than an abrupt change in direction.
Dr. Nelson highlights Telix’s strong commercial business and pipeline and states this transition does not affect near-term milestones or the long-term growth strategy. Future disclosures from the Board will clarify the final chair appointment and additional director appointments.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the month of February, 2026
Commission File Number: 001-42128
Telix Pharmaceuticals Limited
(Translation of registrant’s name into English)
55 Flemington Road
North Melbourne, Victoria 3051, Australia
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
INFORMATION CONTAINED IN THIS FORM 6-K REPORT
On February 3, 2026 (Melbourne, Australia), Telix Pharmaceuticals Limited filed an announcement with the Australian Securities Exchange titled “Chair Resignation, Dr Mark Nelson appointed Interim Chair,” which is attached to this Form 6-K as Exhibit 99.1.
|
99.1
|
Press Release – February 3, 2026
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
Telix Pharmaceuticals Limited
|
|
|
|
|
|
|
Date: February 3, 2026
|
By:
|
/s/ Genevieve Ryan
|
|
|
|
Name: Genevieve Ryan
|
|
|
|
Title: Company Secretary
|
Telix Pharmaceuticals LimitedACN 616 620 369
55 Flemington Road
North Melbourne
Victoria, 3051
Australia
ASX ANNOUNCEMENT
Chair Resignation, Dr. Mark Nelson appointed Interim Chair
Melbourne (Australia) and Indianapolis, IN (U.S.) – 3 February 2026. Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that Ms. Tiffany Olson has resigned as Non-Executive Director and Board Chair, effective today, 3 February 2026.
Dr. Mark Nelson, a long-standing independent, Non-Executive Director since Telix’s listing on the Australian Securities Exchange (ASX), has been appointed as Interim Chair. The Board is in advanced stages of a process to appoint new Non-Executive Directors and is committed to appointing a new Independent Chair as soon as feasible.
Dr. Nelson, Interim Chair of Telix said, “We support Tiffany’s personal decision and extend our sincere thanks for her service to the Board since March 2022, and for the significant contribution she made throughout an important phase in the Company’s evolution. Telix has an exceptionally strong commercial business and pipeline and we expect 2026 to be a pivotal year. We assure investors that this does not impact on the delivery of the near-term milestones and the long-term growth strategy of the Company. The Board is committed to working together to ensure an orderly transition.”
About Telix Pharmaceuticals Limited
Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the ASX (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).
Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook.
Telix Investor Relations (Global)
Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
Email: kyahn.williamson@telixpharma.com
Telix Investor Relations (U.S.)
Annie Kasparian
Telix Pharmaceuticals Limited
Director Investor Relations and Corporate Communications
Email: annie.kasparian@telixpharma.com
This announcement has been authorized for release by the Telix Pharmaceuticals Limited Board of Directors.
Legal Notices
Cautionary Statement Regarding Forward-Looking Statements.
You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.
The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.
This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, including the planned NDA resubmission for TLX101-Px and the planned BLA resubmission for TLX250-Px, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.
Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.
©2026 Telix Pharmaceuticals Limited. All rights reserved.
FAQ
What did Telix Pharmaceuticals (TLPPF) disclose in its latest 6-K filing?
Telix Pharmaceuticals disclosed that Board Chair and Non-Executive Director Tiffany Olson resigned effective 3 February 2026. Long-standing independent director Dr. Mark Nelson was appointed Interim Chair, and the Board is progressing a process to add new Non-Executive Directors and appoint a new Independent Chair.
Who resigned as Board Chair at Telix Pharmaceuticals (TLPPF)?
Ms. Tiffany Olson resigned as Non-Executive Director and Board Chair of Telix Pharmaceuticals, effective 3 February 2026. She had served on the Board since March 2022, contributing during what the company describes as an important phase in its evolution and growth.
Who is the new Interim Chair of Telix Pharmaceuticals (TLPPF)?
Telix Pharmaceuticals appointed Dr. Mark Nelson as Interim Chair following Tiffany Olson’s resignation. Dr. Nelson is a long-standing independent Non-Executive Director who has served since Telix’s listing on the Australian Securities Exchange, providing continuity in Board leadership during the transition period.
Does the Telix Pharmaceuticals (TLPPF) chair change affect its strategy?
According to Interim Chair Dr. Mark Nelson, the leadership change does not affect Telix’s near-term milestones or long-term growth strategy. He states the company has a strong commercial business and pipeline and characterizes 2026 as expected to be a pivotal year for Telix.
What governance steps is Telix Pharmaceuticals (TLPPF) taking after the chair resignation?
Telix’s Board is in advanced stages of appointing new Non-Executive Directors and is committed to naming a new Independent Chair as soon as feasible. The company emphasizes an orderly transition and continued focus on executing its commercial and pipeline objectives during this process.
What type of company is Telix Pharmaceuticals (TLPPF)?
Telix Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapeutic and diagnostic radiopharmaceuticals and related medical technologies. It has international operations across the United States, Europe, Brazil, Canada, the United Kingdom and Japan, with products targeting oncology and rare diseases.